DOCSLIB.ORG

Mandates on Way As Pfizer Vaccine Gets Full U.S. Nod

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mandates on Way As Pfizer Vaccine Gets Full U.S. Nod C M Y K Nxxx,2021-08-24,A,001,Bs-4C,E2 Late Edition Today, sunshine, humid, drying out, warmer, high 88. Tonight, clear, hu- mid, low 72. Tomorrow, mostly sunny, heat persists, humid, high 90. Weather map appears on Page A18. VOL. CLXX ... No. 59,160 © 2021 The New York Times Company NEW YORK, TUESDAY, AUGUST 24, 2021 $3.00 MANDATES ON WAY AS PFIZER VACCINE GETS FULL U.S. NOD F.D.A. Approval Paves Way for Colleges, Hospitals and Corporations to Act By SHARON LaFRANIERE and NOAH WEILAND WASHINGTON — The Food fears that they are experimental, and Drug Administration on Mon- have said they wanted to wait un- day granted full approval to til the agency spent more time Pfizer-BioNTech’s coronavirus studying their safety and fully ap- vaccine for people 16 and older, a proved them. decision that is likely to set off a In a roughly 10-minute address cascade of vaccine requirements on the approval, President Biden by hospitals, colleges and univer- said it should sweep away any lin- sities, corporations and other or- gering doubts about vaccines and ganizations. spur more mandates. Appealing Within hours, the Pentagon, to corporate, state and local lead- CVS, the State University of New ers, he said: “Do what I did last York system and the New York month. Require your employees City school system, among others, to get vaccinated or face strict re- announced that they would en- quirements.” In late July, he an- force mandates they had pre- nounced that all federal employ- pared but made contingent on the ees and on-site contractors must F.D.A.’s action. be vaccinated against the virus or The approval came as the na- be required to submit to regular NICOLE TUNG FOR THE NEW YORK TIMES tion’s fight against the pandemic testing and other measures. An Afghan family in Turkey. The family crossed illegally from Iran and was sent back. Thousands of Afghans have met a similar fate. has intensified again, with the Mr. Biden tried to cast the highly infectious Delta variant bit- F.D.A. approval as an example of ing deeply into the progress that how his administration was mak- the country had made over the ing headway against the pan- first half of the year. The Biden ad- demic, despite overflowing inten- Taliban Demand August Pullout A 1,400-Mile Trek to Turkey ministration hopes the develop- sive care units in some states and ment will motivate at least some an average of more than 1,000 As the U.S. Rushes to Evacuate Only to Be Told to Turn Back of the roughly 85 million Ameri- lives a day lost. He said the death cans who are eligible for shots but toll, while rising, was still far have so far rejected them to lower than it was last winter, be- By MARK LANDLER and MEGAN K. STACK change their minds. cause more than nine in 10 older By CARLOTTA GALL The regulatory move goes a Americans are now vaccinated. As a desperate U.S. effort to On Monday, a State Depart- VAN, Turkey — In the days be- over they would kill us — either in step beyond the emergency use With the F.D.A. yet to authorize evacuate Americans from Af- ment official said that some for- fore the Taliban took Kabul, an Af- fighting or they would recruit us. authorization that the agency a vaccine even on an emergency ghanistan gained momentum on mer Afghan military interpreters ghan woman was doubled over So this was the better option for granted in December. More than basis for children under 12, Mr. Bi- Monday, Taliban leaders rejected or other close U.S. allies, a desig- sobbing on a bench in a bus station the family.” 92 million people have already den also tried to reassure anxious a suggestion from President Bi- nated priority group for evacua- in eastern Turkey, her children Even before the past week’s been fully vaccinated since then parents about the growing num- den that American forces might tions, were being turned away wailing at her feet. harrowing scenes of Afghans with Pfizer doses. Some who have ber of children who are getting in- remain past an Aug. 31 deadline to from the airport by American offi- Fourteen Turkish security and thronging the Kabul airport to es- rejected the vaccines, expressing Continued on Page A12 complete the operation, injecting cials in order to give priority to migration officials swooped down cape the Taliban, many thousands fresh urgency into an already U.S. passport and Green Card on her and other Afghan asylum had been steadily fleeing their frantic process. holders in recent days. The official seekers as our reporting team was country over land, making their REQUIREMENT In a shift, Mayor Bill de Blasio of New York will order American officials are increas- was not authorized to brief the interviewing them, part of an in- way some 1,400 miles across the all Department of Education employees to be vaccinated. PAGE A12 ingly worried that even with the press, and spoke on condition of tensive crackdown by Turkey to length of Iran to the Turkish bor- vast number of Afghans, Ameri- anonymity. apprehend Afghans crossing from der. Their own desperate efforts to cans and people of other national- The official’s account was sup- Iran by the thousands and to pre- escape the Taliban have played ities evacuated in recent days — a ported by interviews with Af- vent journalists from reporting on out in quieter, though no less total of about 10,400 people in the ghans who have approached the their plight. As her husband tried painful, tableaus at remote border Holmes Legacy 24 hours from Sunday to Monday airport in recent days, and with to gather their belongings, the crossings like the one in the east- alone, according to the White American veterans’ groups and woman clutched her stomach and ern city of Van. Haunts Women House — many still remain to be other organizations that have retched. After prolonged ques- In recent months, as the NATO- rescued. In recent days, that oper- tried to organize evacuations for tioning, they were escorted to a led mission in Afghanistan was ation has increasingly focused on interpreters and other Afghans at police vehicle. collapsing, 30,000 Afghans were Atop Start-Ups the Americans still left, over the risk from the Taliban. “We came out of despair,” an- leaving Afghanistan every week, Afghans who worked with the On Monday night, the State De- other Afghan, Gul Ahmad, 17, said. not all but many across the Irani- United States. Continued on Page A6 “We knew if the Taliban had taken Continued on Page A7 By ERIN GRIFFITH SAN FRANCISCO — When Al- ice Zhang set out in 2018 to raise funding for her drug discovery start-up, investors kept asking GABRIELA BHASKAR/THE NEW YORK TIMES Tennesseans in Anguish as Flood Tears Homes and Friends Away her about Theranos, the blood Kathy Hochul was to be sworn testing start-up led by the entre- preneur Elizabeth Holmes that in as governor early Tuesday. This article is by Rick Rojas, Win- had collapsed in scandal. ston Choi-Schagrin and Tariro Others asked, too. At a Stanford Mzezewa. University event, the organizers wanted Ms. Zhang to talk about Cuomo Defiant WAVERLY, Tenn. — With flood- Theranos. One adviser told her waters rising rapidly, 15-year-old Lily Bryant and her older sister that when her start-up came up in And All Alone managed to find some wooden de- conversation, people responded bris to cling to, but it offered only by cracking jokes about Ms. In Final Hours short-term relief. The makeshift Holmes. raft hit a tree and split in two. Ms. Zhang was initially con- “Lily went one way and her sis- fused. Her start-up, Verge Ge- nomics, uses artificial intelligence By LUIS FERRÉ-SADURNÍ ter went the other way, and no one and KATIE GLUECK has seen her since,” said Tarry to aid the discovery of therapeutic On his last day in office, Gov. Lynn Gillinger Holderman, Lily’s drugs. That was completely differ- Andrew M. Cuomo of New York, a aunt. “She was washed away be- ent from Theranos’s business of three-term Democrat once envi- cause the current was so strong.” marketing blood testing machines sioned as a national standard- Lily’s sister, Kailynne, 19, made as a diagnostic tool. Ms. Holmes bearer for his party, appeared it to safety; Lily is missing. had also been accused of criminal alone. Kailynne, Ms. Holderman said, fraud. Ms. Zhang had not. Abandoned by virtually every is devastated. “She blames her- But the pattern was clear. When political ally he once had, the gov- self.” Verge Genomics raised funding ernor held no public event on The scale of the destruction later that year, a prominent indus- Monday, confining his lone ap- from the weekend’s storm in Ten- try columnist wrote an article that nessee came into grim relief on compared Ms. Zhang to Ms. pearance to a prerecorded Monday, as emergency workers Holmes. Although the compar- farewell address where he defi- and those who escaped the worst isons dissipated as her start-up antly cast his resignation as the spent the day searching for loved has grown, Ms. Zhang, 32, said she unavoidable outcome of a rush to ones. At least 21 people were con- hears the same stories from other judgment on sexual harassment firmed dead and about 10 others female founders today, even allegations made against him.
Load more

Recommended publications
  • Squaring Venture Capital Valuations with Reality ONLINE APPENDIX
    Squaring Venture Capital Valuations with Reality ONLINE APPENDIX Will Gornall Sauder School of Business, University of British Columbia Ilya A. Strebulaev Graduate School of Business, Stanford University and National Bureau of Economic Research Sept 2017 Find the full paper here: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2955455 The online appendix follows. Appendix A contains the alternative names for the unicorns in our sample. Appendix B lists companies whose COIs omit information. Appendix C lists companies where we could not locate the most recent COI. Appendix D contains examples of legal text for each of the major terms. Appendix E details the major terms we found for each company in our sample. Appendix F contains comparative statics. Appendix G contains discussion of our return distribution assumptions. Appendix A: Full Legal Names and Other Names for Unicorns in Our Sample Short Name Legal Name Also Known As 23andMe 23andMe, Inc. A123 Systems A123 Systems, Inc. B456 Systems Actifio Actifio, Inc. Adaptive Biotech Adaptive Biotechnologies Adaptive TCR Corporation Age of Learning Age of Learning, Inc. Airbnb Airbnb, Inc. Airbed & Breakfast, Inc Anaplan Anaplan, Inc. AppDirect AppDirect, Inc. Origo Networks Corporation AppDynamics AppDynamics, Inc. Singularity Technologies, Inc. Appnexus AppNexus Inc. Apttus Apttus Corporation Automattic Automattic Inc. Avant Avant, Inc. Avant Credit Corporation Better Place Better Place, Inc. Better Place Holdings; Better PLC Bloom Energy Bloom Energy Corporation Bloom Energy Server; Ion America Corporation Bloom Energy Bloom Energy Corporation Ion America Corporation Blue Apron Blue Apron, Inc. Petridish Media, Inc. Box Box, Inc. Box.Net Buzzfeed BuzzFeed, Inc. Carbon3D Carbon3D, Inc. EIPI Systems, Inc.
    [Show full text]
  • The Effect of FOMO on Stakeholder Enrollment
    The Effect of FOMO on Stakeholder Enrollment Susan L. Young, PhD Kennesaw State University Kennesaw, GA Ph: 470-578-4536 [email protected] Birton Cowden, PhD Kennesaw State University Kennesaw, GA Ph: 470-578-36781 [email protected] 1 The Effect of FOMO on Stakeholder Enrollment Abstract Stakeholder theory suggests dishonest ventures would struggle with stakeholder enrollment, limiting resource access and ultimately failing. Yet cases exist where amoral entrepreneurs do enroll stakeholders through deceit. We propose “fear of missing out” on an opportunity facilitates enrollment by encouraging stakeholder acceptance of information asymmetry. To illustrate we use exemplar Theranos: a biotech firm which convinced stakeholders it would revolutionize healthcare, rising to a $10 billion valuation through 15 years of sustained deceit. We contribute to theory by demonstrating the dark side of stakeholder enrollment, where opportunism increases venture power over stakeholders, and deceit can endure long past start up. Keywords: stakeholder theory, stakeholder enrollment, entrepreneurial deceit, fear of missing out, legitimacy 2 The Effect of FOMO on Stakeholder Enrollment “Theranos had demonstrated a commitment to investing in and developing technologies that can make a difference in people’s lives, including for the severely wounded and ill. I had quickly seen tremendous potential in the technologies Theranos develops, and I have the greatest respect for the company’s mission and integrity.” (Johnson, 2015) — 4-star General Jim Mattis, U.S. Marine Corps, Retired U.S. Secretary of Defense, 2017-2019 The Securities and Exchange Commission today charged Silicon Valley-based private company Theranos Inc., its founder and CEO Elizabeth Holmes, and its former President Ramesh “Sunny” Balwani with raising more than $700 million from investors through an elaborate, years-long fraud in which they exaggerated or made false statements about the company’s technology, business, and financial performance.
    [Show full text]
  • Debates9 963919 9878034 Final Group Paper
    Group 9 Against Edison- Potential Patients Kendall Travis, Charles Goff, Jenna Lang, Isaiah Watts Position: Against Edison Perspective: Potential Patients Strategy: Against Edison- Potential Patients Background As appealing as Theranos’s low prices are for blood testing, the cost of that is results that are far from the truth. The lab technicians who work at Theranos have little faith in the tests that they do. They feel criminal, uncertain, and concerned enough to the point where they would never do a test there or allow a family member to. For anyone to work there, non-disclosure agreements have to be signed. Clearly the company is hiding something. And for the many workers who have quit Theranos, they have spoken up about how defective everything is there, knowing it would result in the harassment and hounding from Theranos’s team of lawyers and higher up individuals, a price they were willing to pay to warn potential patients like us. The life-changing effects of Theranos’s work have all been anecdotal claims from Elizabeth Holmes, her work is discovered in isolation, and also her work is impossible to achieve with a single drop of blood according to medical experts. All of these are signs of bogus science that can be tied to Theranos. The list of concerns we have compiled comes from watching The Inventor: Out for Blood in Silicon Valley on HBO. The documentary alone has made it easy for us, as potential patients, to see that Theranos is a fraudulent and unfit company that is unethical for any patient to go to.
    [Show full text]
  • Theranos' Bad Blood
    Theranos’ Bad Blood In 2003, Stanford University student Elizabeth Holmes founded the health care company Theranos. The goal of the company was to revolutionize health care. Beginning with the goal of creating a patch to deliver drugs, the company instead shifted focus to developing a simple and effective method for blood diagnosis. Holmes dropped out of Stanford and began raising millions of dollars in funding. The company claimed that its technology could offer over 240 tests from just a prick of the finger. Test results could be delivered to a patient’s phone in hours, and a single test would cost less than half of the reimbursement rate of Medicare and Medicaid. Blood could be diagnosed easily without the need for many vials of blood drawn from patients’ veins or expensive lab work. By 2014, the company was valued at $9 billion, of which Holmes held a majority stake. Many investors backed the company based on the promise of the technology. Holmes received glowing profiles in news magazines, was featured on television shows, and presented keynote addresses at tech conferences. But the excitement of investors and the promise of the technology did not translate into success. Operating largely in a cloak of secrecy, the company could never validate its claims about its blood sampling technology, and many of its lab results went unchecked. In 2015, journalist John Carreyrou investigated the company for an article in The Wall Street Journal. He disclosed problems in the company’s equipment and testing methods. He found that the company did not even use its own technology in tests and often relied on older technology from other companies.
    [Show full text]
  • Executive Branch Personnel Public Financial Disclosure Report (OGE Form 278E)
    Nominee Report | U.S. Office of Government Ethics; 5 C.F.R. part 2634 | Form Approved: OMB No. (3209-0001) (March 2014) Executive Branch Personnel Public Financial Disclosure Report (OGE Form 278e) Filer's Information DeVos, Elisabeth P ("Betsy") Secretary, Department of Education Other Federal Government Positions Held During the Preceding 12 Months: Names of Congressional Committees Considering Nomination: ● Committee on Health, Education, Labor, and Pensions Electronic Signature - I certify that the statements I have made in this form are true, complete and correct to the best of my knowledge. /s/ DeVos, Elisabeth P ("Betsy") [electronically signed on 01/19/2017 by DeVos, Elisabeth P ("Betsy") in Integrity.gov] Agency Ethics Official's Opinion - On the basis of information contained in this report, I conclude that the filer is in compliance with applicable laws and regulations (subject to any comments below). /s/ Goodridge-Keiller, Marcella, Certifying Official [electronically signed on 01/19/2017 by Goodridge-Keiller, Marcella in Integrity.gov] Other review conducted by /s/ Sprague, Marcia, Ethics Official [electronically signed on 01/19/2017 by Sprague, Marcia in Integrity.gov] U.S. Office of Government Ethics Certification /s/ Shaub, Walter M, Certifying Official [electronically signed on 01/19/2017 by Shaub, Walter M in Integrity.gov] 1. Filer's Positions Held Outside United States Government # ORGANIZATION NAME CITY, STATE ORGANIZATION POSITION HELD FROM TO TYPE 1 The Stow Company - Holland, Inc. See Endnote Holland, Corporation Chief Creative 5/2016 11/2016 Michigan Officer 2 The Stow Company - Holland, Inc. See Endnote Holland, Corporation Director 6/1994 11/2016 Michigan 3 RCB Main Floor, LLC (d/b/a "Reserve GR, See Endnote Grand Rapids, Corporation Director 3/2010 11/2016 LLC") Michigan 4 The Stow Company See Endnote Holland, Corporation Director 5/2010 11/2016 Michigan 5 Neurocore, LLC See Endnote Grand Rapids, Corporation Member/Manag 2/2009 11/2016 Michigan er 6 Windquest Group, Inc.
    [Show full text]
  • The Bleeding Edge: Theranos and the Growing Risk of an Unregulated Private Securities Market
    University of Miami Business Law Review Volume 28 Issue 2 Article 8 September 2020 The Bleeding Edge: Theranos and the Growing Risk of an Unregulated Private Securities Market Theodore O'Brien Follow this and additional works at: https://repository.law.miami.edu/umblr Part of the Business Organizations Law Commons, and the Securities Law Commons Recommended Citation Theodore O'Brien, The Bleeding Edge: Theranos and the Growing Risk of an Unregulated Private Securities Market, 28 U. Miami Bus. L. Rev. 404 (2020) Available at: https://repository.law.miami.edu/umblr/vol28/iss2/8 This Comment is brought to you for free and open access by the Journals at University of Miami School of Law Institutional Repository. It has been accepted for inclusion in University of Miami Business Law Review by an authorized editor of University of Miami School of Law Institutional Repository. For more information, please contact [email protected]. The Bleeding Edge: Theranos and the Growing Risk of an Unregulated Private Securities Market Theodore O’Brien* America’s securities laws and regulations, most of which were created in the early twentieth century, are increasingly irrelevant to the most dynamic emerging companies. Today, companies with sufficient investor interest can raise ample capital through private and exempt offerings, all while eschewing the public exchanges and the associated burdens of the initial public offering, public disclosures, and regulatory scrutiny. Airbnb, Inc., for example, quickly tapped private investors for $1 billion in April of 2020,1 adding to the estimated $4.4 billion the company had previously raised.2 The fundamental shift from public to private companies is evidenced by the so-called “unicorns,” the more than 400 private companies valued at more than $1 billion.
    [Show full text]
  • Theranos Phenomenon – Part 5: Theranos’ Presentation at the American Association for Clinical Chemistry Annual Conference 2016
    Clin Chem Lab Med 2016; 54(10): e313–e314 Letter to the Editor Eleftherios P. Diamandis* and Mario Plebani Theranos phenomenon – Part 5: Theranos’ presentation at the American Association for Clinical Chemistry Annual Conference 2016 DOI 10.1515/cclm-2016-0737 Master, two highly recognized and respected clinical Accepted for publication August 18, 2016; previously published chemists, who did a good job in asking pertinent ques- online August 30, 2016 tions to Ms. Holmes and her associates. In this respect, AACC lived up to the expectations of high standards and Keywords: diagnostics; new technologies. impartiality for this presentation. Holmes presented to a large and curious, if not To the Editor, hostile, audience. She avoided talking about Theranos’ past and the difficulties of her company [1–7]. She also The widely anticipated presentation of Theranos at the made it clear that her presentation would focus on the Annual Conference of the American Association for future, not the past, and she distanced herself from the Clinical Chemistry (AACC) was finally given on Monday, previous “Edison” instrument and introduced a new August 1st, 2016 at the Philadelphia Convention Center. analyzer named “MiniLab”. In the first part of her pres- This journal has followed the Theranos story closely over entation, Ms. Holmes described the engineering behind the last 2 years and provided frequent updates [1–4]. Eliza- the MiniLab and explained that it is a compact desktop beth Holmes, the Chief Executive of Theranos, presented device that houses a mini spectrophotometer, a mini- to an audience of over 2500 clinical chemists and other luminometer, and mini-flow-cytometer and a mini-PCR laboratory scientists, as well as to an impressive number machine, along with a centrifuge.
    [Show full text]
  • Bad Blood Secrets and Lies in a Silicon Valley Startup by John Carreyrou
    Bad Blood Secrets and Lies in a Silicon Valley Startup By John Carreyrou At its peak in 2013/14, Theranos had a valuation of $10 billion, representing incredible growth in the 10 years since its incorporation in 2003. The company claimed that it had developed and commercialized a revolutionary new blood testing solution. Viewed as a stunning start-up success, the Theranos board was a roster of well-known government and business leaders, including Henry Kissinger, James Mattis and Riley Bechtel. The buzz around Theranos was electric, and high-profile investors such as Betsey DeVos, the Walton family, and Rupert Murdoch invested hundreds of millions of dollars to fund the company. At the helm was Elizabeth Holmes, founder and CEO. Holmes dropped out of Stanford Engineering in 2004 and used her tuition fees to help fund her brainchild. Blond, attractive, and possessed of an unusually deep baritone voice, Holmes was listed by Forbes as one of America’s Richest Self-Made Women in 2015, with a net worth of over $4 billion. That same year, however, it all came crashing down when investigative reporter John Carreyrou of the Wall Street Journal revealed that the Theranos technology did not work as claimed. Carreyrou’s exhaustive research uncovered a web of lies and cover-ups, dating back to the earliest days at Theranos. Today, the company is worth nothing and has been dissolved, investors have lost multi- millions, and Elizabeth Holmes was charged with massive fraud by the SEC in March, 2018. This riches-to-rags story has captured the public’s imagination, and a movie based on Carreyrou’s book (starring Jennifer Lawrence as Elizabeth Holmes), is slated for release in 2020.
    [Show full text]
  • Inovio Pharmaceuticals (INO) – Bad Blood the COVID-19 Version of Theranos – Target Price $1
    April 27, 2020 Inovio Pharmaceuticals (INO) – Bad Blood The COVID-19 Version of Theranos – Target Price $1 It was less than 10 years ago when Theranos was the talk of the med tech community as the mysterious startup claimed breakthrough advancements with the ability to quickly process over 240 laboratory tests with a prick of the finger. Seemed too good to be true? Well, as you know, the rest of the story is business history. Fast forward 10 years and we are now facing the largest global pandemic in generations. As the greatest scientific minds globally are working tirelessly to find a cure, Inovio Pharmaceuticals (INO) claims to have developed a vaccine in just 3 hours under the same scientific team that has spent decades deceiving investors. It’s been over 40 years since Inovio was founded, yet the company has NEVER brought a product to market, and all the while insiders have enriched themselves with hefty salaries and large stock sales. In this report, Citron will detail why Inovio shareholders have been “Theranosed” and why the SEC should immediately halt this blatant stock promotion. The Secret Algorithm Much like Theranos, Inovio claims to have a “secret sauce” that, miraculously, no pharma giant has been able to figure out. This is the same “secret sauce” that supposedly developed a vaccine for COVID-19 in just 3 hours. Simply put, the management team at Inovio is a group of charlatans. Just look at this exchange with 60 minutes and Inovio’s SVP of R&D Researcher Kate Broderick: Kate Broderick: All we need is that genetic code.
    [Show full text]
  • How and Why Did It Go So Wrong?: Theranos As a Legal Ethics Case Study
    Georgia State University Law Review Volume 37 Issue 2 Winter 2021 Article 6 3-1-2021 How and Why Did it Go So Wrong?: Theranos as a Legal Ethics Case Study G.S. Hans Vanderbilt University, [email protected] Follow this and additional works at: https://readingroom.law.gsu.edu/gsulr Part of the Legal Education Commons, and the Legal Ethics and Professional Responsibility Commons Recommended Citation G.S. Hans, How and Why Did it Go So Wrong?: Theranos as a Legal Ethics Case Study, 37 GA. ST. U. L. REV. 427 (2021). Available at: https://readingroom.law.gsu.edu/gsulr/vol37/iss2/6 This Article is brought to you for free and open access by the Publications at Reading Room. It has been accepted for inclusion in Georgia State University Law Review by an authorized editor of Reading Room. For more information, please contact [email protected]. Hans: How and Why Did it Go So Wrong? HOW AND WHY DID IT GO SO WRONG?: THERANOS AS A LEGAL ETHICS CASE STUDY G.S. Hans* ABSTRACT The Theranos saga encompasses many discrete areas of law. Reporting on Theranos, most notably John Carreyrou’s Bad Blood, highlights the questionable ethical decisions that many of the attorneys involved made. The lessons attorneys and law students can learn from Bad Blood are highly complex. The Theranos story touches on multiple areas of professional responsibility, including competence, diligence, candor, conflicts, and liability. Thus, Theranos serves as a helpful tool to explore the limits of ethical lawyering for Professional Responsibility students. This Article discusses the author’s experience with using Bad Blood as an extended case study in a new course on Legal Ethics in Contemporary Practice.
    [Show full text]
  • Theranos Phenomenon: Promises and Fallacies
    Clin Chem Lab Med 2015; 53(7): 989–993 Opinion Paper Eleftherios P. Diamandis* Theranos phenomenon: promises and fallacies DOI 10.1515/cclm-2015-0356 Received April 8, 2015; accepted April 15, 2015; previously published Introduction online May 9, 2015 My Vice-President of Operations at a major teaching Hospital in Toronto asked me to update him on a “new” company called Theranos that promises to revolutionize Abstract: Recently, spectacular advances in diagnostic diagnostics by offering multi-analyte testing at bargain technologies, genomics, etc. offer unprecedented oppor- prices in commercial outlets such as pharmacies [1]. The tunities for widespread testing of asymptomatic individu- interest of my Vice-President was triggered by an inquiry als, in the hope that this testing will unravel early disease from the recently appointed Hospital President, who was signs which could lead to preventative or more effective wondering as to how Theranos could do diagnostic testing therapeutic measures. In particular, one commercial at 10% of the cost of centralized laboratories. I assumed organization, Theranos, promises to revolutionize diag- from these discussions that my administrators are seri- nostics by offering multi-analyte testing at low prices in ously thinking of adopting some kind of a “Theranos commercial outlets, thus challenging the current para- model” to drastically reduce current laboratory costs. digm of targeted and centralized diagnostic testing. In Theranos seems to be a highly successful enterprise this paper, I analyze the Theranos technology and their that managed to raise hundreds of millions of dollars in promises, and contrast this information with the cur- multiple rounds of fundraising and has a stellar govern- rently used technologies, to show that most of the com- ance body.
    [Show full text]
  • 03. Style Approach
    IMSA Leadership Education and Development “The minute you start compromising for the sake of massaging somebody's ego, that's it, game over.” - Gordon Ramsay Time Period and Situation Research regarding the Style Approach Theory is thought to have begun around the 1940s at Ohio State University and the University of Michigan that served to determine the most significant behaviors exhibited by leaders. One of the first identifications of the theory was that leadership is divided into task and relationship behaviors, which serves as the basis of the division between the two aspects of the theory. Later, in the 1960s, further studies were conducted by the pair Blake and Mouton that explored how managers used task vs. relationship behaviors in an organizational setting. Following this era, the Leadership (Managerial) Grid was created and encompassed the ideas of all three studies on a scale of production centered behaviors vs relationship-focused behaviors (Northouse 71-76). Agenda 1. Theories a. Style Approach to Leadership i. Task vs. Relationship Oriented 2. Concepts a. Situational Awareness b. Social Identity Theory c. Social Norm Theory 3. Style Approach Examples a. Gordon Ramsay i. Situational Awareness b. Elizabeth Holmes i. Task-oriented style approach 4. Activities a. Situational Awareness: Task vs Relationship b. A Building Activity: Task Oriented/Relationship Oriented Behaviors 5. Supplemental Materials 6. References Revised July 2019 IMSA Leadership Education and Development Student Objectives: 1. Students will understand Style Approach and be able to differentiate between task and ​ ​ ​ relationship-oriented Style Approach. ​ 2. Students will understand the concepts behind Social Identity Theory and Social Norm ​ ​ ​ Theory and how they are incorporated into leadership.
    [Show full text]